For research use only. Not for use in humans.

Figitumumab (Anti-IGF1R / CD221)

Synonyms: CP-751871

Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.

Figitumumab (Anti-IGF1R / CD221)

Quality Control

Batch: A294201 Purity: 99% Protein concentration: 5.223mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation IGF-1R Insulin Receptor Others
Linsitinib (OSI-906) 206 IRR
NVP-AEW541 65 FLT3,Tek,FLT1
GSK1904529A 26
NVP-ADW742 24
BMS-536924 26 FAK,MEK,LCK
AG-1024 27
GSK1838705A 18 ALK
BMS-754807 54 TrkB,Met,TrkA
PQ 401 3
Ginsenoside Rg5 0
XL228 0 ABL T315I,LYN,Aurora A
Picropodophyllin (PPP) 45
AZD3463 7 ALK
S961 3
Nordihydroguaiaretic acid (NDGA) 1 p300,HER2,lipoxygenase
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
References

Product Details

CAS No. 943453-46-1
Molecular Weight 146
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.